Whereas high-dose CDN monotherapy was sufficient to control tumor growth via innate immune responses, lower doses of CDN, coupled with radiotherapy, could stimulate the adaptive immune response involving CD8+ T cells [163]. The gene discussed is CD8A; the disease is neoplasm.